PETACH TIKVA, Israel, May 18, 2016 /PRNewswire/ --
Emerald Medical Applications Corp. (OTCQB: MRLA) ("Emerald" or the "Company"), the Israeli-based company engaged in the development and sale of DermaCompare™, its proprietary artificial intelligence technology and application for the early diagnosis of melanoma and other skin cancers, today announced that Dr. Ben-Zion Weiner has joined the Company's Scientific Advisory Board.
From 1975 to 2012, Dr. Weiner held executive positions with Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and its subsidiaries ("Teva"). He was Vice President of Global Products of Teva from 2005 to 2011 where he was responsible for global Generic and Innovative Research and Development.
Dr. Weiner was also a Member of the Core Management Committee.
Dr. Weiner holds a B.Sc. Degree in General Chemistry and Biochemistry, graduating with distinction at the Hebrew University, Jerusalem, a M.Sc. Degree in Organic Chemistry, graduating with distinction at the Hebrew University of Jerusalem, and a Ph.D. Degree from the Hebrew University, Jerusalem. Dr. Weiner did his Post-Doctorate studies at Schering Plough Corporation in Bloomfield, New Jersey, on "Exploratory work of new drugs, research in organic chemistry, and pharmacology." Dr. Weiner received twice the Rothschild Prize for Innovation/Export for the development of Copaxone(R) for Multiple Sclerosis and for the development of alpha D3 for Dialysis and Osteoporosis.
Dr. Weiner commented, "I am pleased with the high potential of Emerald's DermaCompare™ technology. My pharmaceutical background will allow me to consult and advise the company on how to maximize current and future applications for the technology. Dr. Weiner went on saying: "I am honored and privileged to join forces with Professor Perry Robbins and Lior Wayn, CEO of Emerald Medical Applications Corp., stated, "I would like to officially welcome Dr. Weiner to our Scientific advisory board. His qualifications and expertise in the areas of chemistry, pharmacology and pharmaceutical products will undoubtedly be of significant value as we explore to maximize our DermaCompare's potential. I believe that our ability to combine the power of artificial intelligence with the utility of a mobile app will revolutionize the way we detect and diagnose melanoma and, in the future, other skin conditions.
About Emerald Medical Applications Corp
Emerald Medical Applications is an Israeli-based medical technology company that utilizes proprietary military image processing technology and state of the art data analytics to improve the analysis of medical images. Emerald's flagship solution, DermaCompare™, is an FDA Class #1 approved, HIPPA-compliant, skin cancer (melanoma) screening platform that enables physicians to identify and monitor changes in their patients' skin health, specifically the early detection of cancerous moles and skin anomalies.
The DermaCompare™ patient application is available in Mac or Android based platforms and works using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography ("TBP") images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patient's previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficiently than other means of diagnosis.
For more information, visit: http://www.dermacompare.com/
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about Emerald's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Emerald or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Emerald with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Emerald's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Emerald's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Emerald's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Emerald's filings with the SEC. In addition, Emerald operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Emerald does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Reference is made to the disclosure under "risk factors" included in our Registration Statement on Form S-1 which was declared effective by the U.S. Securities and Exchange Commission on January 20, 2016.
Lior Wayn, CEO
SOURCE Emerald Medical Applications Corp.